Ultragenyx Pharmaceutical
RARE
#4494
Rank
C$3.49 B
Marketcap
C$35.50
Share price
4.23%
Change (1 day)
-29.57%
Change (1 year)

Earnings for Ultragenyx Pharmaceutical (RARE)

Earnings in 2026 (TTM): -C$0.75 Billion

According to Ultragenyx Pharmaceutical's latest financial reports the company's current earnings are C$0.66 Billion. In 2025 the company made an earning of -C$0.72 Billion a decrease over its 2024 earnings that were of -C$0.71 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Ultragenyx Pharmaceutical from 2013 to 2026

Annual earnings

Year Earnings Change
2026 (TTM) -C$0.75 Billion3.97%
2025 -C$0.72 Billion1%
2024 -C$0.71 Billion-6.99%
2023 -C$0.76 Billion-17.65%
2022 -C$0.93 Billion55.52%
2021 -C$0.6 Billion178.53%
2020 -C$0.22 Billion-59.64%
2019 -C$0.53 Billion1.46%
2018 -C$0.52 Billion12.9%
2017 -C$0.47 Billion32.63%
2016 -C$0.35 Billion67.87%
2015 -C$0.21 Billion160.2%
2014 -C$79.43 Million66.64%
2013 -C$47.67 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Lexicon Pharmaceuticals
LXRX
-C$95.94 Million-87.22%๐Ÿ‡บ๐Ÿ‡ธ USA
Esperion Therapeutics
ESPR
-C$38.39 Million-94.89%๐Ÿ‡บ๐Ÿ‡ธ USA
Amicus Therapeutics
FOLD
C$0.26 M-100.04%๐Ÿ‡บ๐Ÿ‡ธ USA
BioMarin Pharmaceutical
BMRN
C$0.53 B-171.86%๐Ÿ‡บ๐Ÿ‡ธ USA